Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Moodys
Colorcon
McKesson
Johnson and Johnson

Last Updated: May 26, 2022

JETREA Drug Profile


✉ Email this page to a colleague

« Back to Dashboard

Summary for Tradename: JETREA
Recent Clinical Trials for JETREA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Katholieke Universiteit LeuvenPhase 1
Universitaire Ziekenhuizen LeuvenPhase 1
KU LeuvenPhase 1

See all JETREA clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for JETREA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for JETREA Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Thrombogenics Inc. JETREA ocriplasmin Injection 125422 See Plans and Pricing 2020-12-21 Company disclosures
Thrombogenics Inc. JETREA ocriplasmin Injection 125422 See Plans and Pricing 2022-12-06 Company disclosures
Thrombogenics Inc. JETREA ocriplasmin Injection 125422 See Plans and Pricing 2022-12-06 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for JETREA Derived from Patent Text Search

These patents were obtained by searching patent claims

International Patents for JETREA

Country Patent Number Estimated Expiration
China 100577202 See Plans and Pricing
World Intellectual Property Organization (WIPO) 0250290 See Plans and Pricing
Germany 60131450 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2004052228 See Plans and Pricing
Japan 5426063 See Plans and Pricing
Portugal 1343903 See Plans and Pricing
Norway 2013016 See Plans and Pricing
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for JETREA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
SPC/GB13/048 United Kingdom See Plans and Pricing PRODUCT NAME: JETREA - OCRIPLASMIN; REGISTERED: UK EU/1/13/819/001 20130313
PA2013020,C1581254 Lithuania See Plans and Pricing PRODUCT NAME: OCRIPLASMINUM (MICROPLASMINUM); REGISTRATION NO/DATE: EU/1/13/819/001 20130313
122013000063 Germany See Plans and Pricing PRODUCT NAME: JETREA - OCRIPLASMIN; REGISTRATION NO/DATE: EU/1/13/819/001 20130313
PA2013020 Lithuania See Plans and Pricing PRODUCT NAME: OCRIPLASMINUM (MICROPLASMINUM); REGISTRATION NO/DATE: EU/1/13/819/001 20130313
47/2013 Austria See Plans and Pricing PRODUCT NAME: OCRIPLASMIN; REGISTRATION NO/DATE: EU/1/13/819/001 (MITTEILUNG) 20130315
122013000076 Germany See Plans and Pricing PRODUCT NAME: MIKROPLASMIN; REGISTRATION NO/DATE: EU/1/13/819/001 20130313
CR 2013 00039 Denmark See Plans and Pricing PRODUCT NAME: OCRIPLASMIN; REG. NO/DATE: EU/1/13/819/001 20130313
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Colorcon
Johnson and Johnson
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.